Liaoning Cheng Da Co (600739) Fair Value & Analysis

Healthcare · CN · Market cap 16.6B CNY

Below-average quality, and screening another 24% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥10.28). The favourable scenario is already priced in.
• Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.

How to read this chart

60‑month range ¥7.27 – ¥25.12 · fair‑value band ¥5.99 – ¥10.28 · the ¥10.89 price screens above the ¥8.23 fair value. Dashed = 300-day average. As of Aug 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Liaoning Cheng Da Co (600739) currently trades at ¥10.89, while our model-based Fair Value estimate is ¥8.23, implying the stock looks roughly 24.4% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Liaoning Cheng Da Co generated revenue of 9.4B CNY at a net margin of 10.0%. Revenue declined 19.1% year over year. It earns a return on equity of 1.5%. Net debt stands at 4.4B CNY. Fundamentals as of Aug 9, 2026

Our scenario range runs from ¥5.99 (bear case) to ¥10.28 (bull case); at ¥10.89, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -24%, 600739 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Economic Profit (¥13.32) versus Earnings-Based (¥1.82). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Liaoning Cheng Da Co., Ltd. engages in biopharmaceutical, financial investment, supply chain, energy development, and other businesses in China and internationally.

Full company description

Liaoning Cheng Da Co., Ltd. engages in biopharmaceutical, financial investment, supply chain, energy development, and other businesses in China and internationally. The company is involved in the import and export of textiles, and clothing, as well as the trade of bulk commodities, such as coal, steel, and aquatic products; and oil shale mining, shale oil production, and sale business. It also offers financial service enterprises including securities, insurance, and funds; rabies vaccines for human use and inactivated Japanese encephalitis vaccines for human use; medical industry investment and medical enterprise management consulting; and computer software and hardware technology development, technology consulting, technology transfer, technical services, and selling of medical equipment and other businesses. The company was founded in 1991 and is headquartered in Dalian, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Liaoning Cheng Da Co reported revenue of ¥9.9B in FY2025 versus ¥18.4B in FY2021, a compound −14.3%/yr. Reported net income was ¥737M in FY2025, compounding −23.6%/yr from FY2021.

600739 screens 24% overvalued. Compare with McKesson Corporation →

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.